PLATE 05 · DOSE, ROUTE, AND PROVENANCE
GHK-Cu dosage research: the concentrations, routes, and stability studied
What was administered, to which species, by which route — and where the human pharmacokinetic record simply does not exist. A research-context catalogue, not a dosing guide.
GHK-Cu dosage in the research context
GHK-Cu dosage in the research record spans nine orders of magnitude of concentration and a half-dozen routes, because the molecule has been studied in cell culture, in rodents, and in topical human formulations — never as a standardized systemic human protocol. This page catalogues what was administered in studies. It is not a dosing guide, and no human dosing recommendation appears here.
In human fibroblast cultures, collagen synthesis onset occurs between 10^-12 and 10^-11 M and peaks near 10^-9 M [1]. Topical cosmetic and clinical formulations run roughly 0.05% to 2% (w/w) in creams, serums, and gels [3]. Rodent systemic studies used intraperitoneal doses spanning micrograms-per-gram to milligrams-per-kilogram depending on the model. The neuroprotection mouse studies delivered GHK intranasally at 15 mg/kg, daily or three times weekly [8][13]. The human hair-loss RCT applied a 5-ALA + GHK topical complex at 50-100 mg/mL [4]. These are study parameters, not instructions.
Half-life, routes, and stability
No rigorous human pharmacokinetic half-life has been published for GHK-Cu. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases; a rat HPLC study documented rapid metabolism of GHK to the dipeptide histidyl-lysine after intravenous dosing [16]. Secondary literature cites a short systemic elimination half-life on the order of 1-2 hours, with the copper-chelated complex more stable than free GHK. Topical application forms a dermal copper depot — about 97 ug/cm^2 retained over 48 hours — giving prolonged local availability [5].
Stability is chemistry, not marketing. The GHK-Cu complex has a very high copper stability constant (log K approximately 16.4), which limits pro-oxidant free-copper release, and it is most stable near pH 5-6.5 at a 1:1 copper-to-peptide ratio [7]. The blue-violet color of a reconstituted solution is the expected Cu(II) absorption and indicates an intact complex; brown or green shifts indicate oxidation or precipitation. Strong reducing agents and low-pH actives break the complex — a formulation fact catalogued plainly below.
ACCESS NOTE · THE CLINICAL BOUNDARY
A study route is not a care protocol
For GHK-Cu, the boundary between a published study parameter and patient care remains part of the specimen label: Promise Peptides (mypromise.com) represents a licensed, clinician-led route for prescription-only peptide care, not evidence that any concentration or route catalogued above is an established human protocol.
Copper Peptide Side Effects and Tolerability in the Research
The copper peptide side effects documented in the GHK-Cu research record are modest and route-dependent, and they sit against a long topical-cosmetic safety history. The GHK-Cu side-effect signal that recurs is localized hyperpigmentation, reported with some topical copper-peptide applications — for example, in roughly 40% of subjects in one acne-scar microneedling study — alongside a CO2-laser post-procedure RCT (n=13) that found no objective benefit despite higher patient satisfaction [9]. Beyond these, the chief copper peptide side effects concern is chemical rather than biological: ascorbic acid and other low-pH actives can reduce the Cu(II) ion and destroy both actives, a formulation and user-error risk [7]. A theoretical copper-accumulation or copper-zinc-balance risk exists with prolonged systemic use, though no human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record. These are catalogued as research observations and provenance notes, not as a clinical safety profile.
Is Copper Peptide Safe? Regulatory and Safety Context
Whether a copper peptide is safe depends entirely on form and route, and the regulatory record draws a sharp line. Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU, and UK with a long marketed safety history [3]. Injectable, oral, or other systemic GHK-Cu is an unapproved research chemical: there is no FDA- or EMA-approved drug product for any indication by any route, and no validated human pharmacokinetic data — half-life, Cmax, bioavailability, tissue distribution — for systemic dosing [16]. Community-circulated injectable protocols have no peer-reviewed basis. The molecule's high copper stability constant (log K approximately 16.4) limits free-copper release [7], and rodent studies kept copper loads below the ion-toxicity threshold, but those are mechanistic reassurances about chemistry, not clinical safety clearances for human systemic use. This site reports that regulatory boundary as it stands; it does not advise crossing it.
What Are the Downsides of Copper Peptides?
Key caveats: no approved therapeutic indication; most evidence is in vitro or rodent; localized hyperpigmentation has been reported with some topical copper-peptide use; a CO2-laser post-procedure RCT (n=13) found no objective benefit; and vitamin C or low-pH actives can destabilize the complex [3][5][9]. Systemic dosing protocols circulated in community contexts have no peer-reviewed pharmacokinetic basis [16].
What Shouldn't Be Combined with GHK-Cu?
Strong reducing agents and low-pH actives — notably ascorbic acid (vitamin C) below about pH 3.5, plus AHAs and BHAs — can reduce the Cu(II) ion or compete for copper and break the complex [7]. The complex is most stable near pH 5-6.5 at a 1:1 copper-to-peptide ratio [7]. This is a formulation and user-error risk, not a biological side effect.
Is GHK-Cu Safe for Long-Term Use?
Topical Copper Tripeptide-1 has a long cosmetic safety record, but there is a theoretical copper-accumulation and copper-zinc-balance concern with prolonged systemic use and no long-term human safety data for injectable or systemic GHK-Cu. The high copper stability constant (log K approximately 16.4) limits free-copper release [7], and rodent studies used copper loads below the ion-toxicity threshold.
Is Copper Peptide Safe? Regulatory and Safety Context
Topical Copper Tripeptide-1 is a legal cosmetic ingredient with a long safety record in the US, EU, and UK; injectable or systemic GHK-Cu is an unapproved research chemical with no established regulatory pathway [3]. There is no FDA- or EMA-approved drug product for any indication, and no validated human pharmacokinetic data for systemic use [16].